Latest News

The drug Valsartan (a generic version of Diovan), which is prescribed to treat high blood pressure and prevent heart failure, has been recalled worldwide after it was found to contain N-nitrosodimethylamine (NDMA), a known carcinogen. Valsartan contamination from a Chinese manufacturing plant may date back to 2012, potentially exposing many patients to Valsartan cancer risk, liver damage and tumors. It has been on the market for 15 years.

Several insurance companies are refusing to cover emergency room visits, telling their policy holders/patients that they must pay for emergency services if the insurer deems the ER visit “unnecessary”. This new policy began with Anthem Insurance Company, which decides whether to pay an emergency room bill based on a doctor’s diagnosis — not the reason the patient went to the hospital. Health experts say this new policy will scare patients away from emergency departments – patients who could potentially have a life-threatening condition. Insurance attorneys are filing complaints against such insurers, claiming they violate federal and state law.

Intragastric balloon lawsuits are now taking shape after a dozen deaths were attributed to the recently-approved form of weight-loss surgery. As of June 2018, the Food and Drug Administration linked 12 deaths to the implantation of what appears to be a defective medical device. The most recent reports implicate the Orbera Intragastric Balloon, manufactured by Apollo Endosurgery Inc. and the Integrated Dual Balloon, which is manufactured by ReShape Lifesciences. Similar devices are manufactured by Obalon Therapeutics and Spatz Medical.

Washington, DC: A $16.8 million settlement has been reached in an unpaid overtime class action lawsuit pending against Kellogg's Co. If the preliminary settlement receives final approval it will end four years of litigation.